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Unstable angina and non–ST-segment elevation myocardial
infarction (NSTEMI) comprise a growing percentage of
patients with acute coronary syndromes (ACS) and are
emerging as a major public health problem worldwide,
especially in Western countries, despite significant improve-
ments and refinements in management over the past two
decades. In the U.S. alone, nearly 1.5 million people suffer
from acute MI each year with more than one million people
admitted to coronary care units annually, the great majority
of whom now present with NSTE ACS (1). Consequently,
much attention has been directed toward optimizing the
diagnosis and management of such patients, particularly in
light of the continued evolution of catheter-based interven-
tions and newer pharmacologic strategies that afford more
complete platelet and thrombin inhibition and which, when
used together, appear to have an important synergistic effect
in reducing prognostically important ischemic events.
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Two distinct approaches have emerged over the past 10 to
15 years in the management of patients with NSTE ACS:
1) a “routine early invasive” strategy consisting of prompt
diagnostic coronary angiography within 24 to 48 h in all
patients with ACS or NSTEMI followed by myocardial
revascularization—generally with percutaneous coronary
intervention (PCI) and stenting—if coronary anatomy is
amenable to this approach; and 2) a “conservative” or
“ischemia-guided” strategy that consists of rapidly intensi-
fying medical therapy with aggressive antiplatelet, anti-
thrombin, and anti-ischemic therapy for a predefined treat-
ment interval, ranging generally from 24 to 36 h to several
days, after which intravenous medications are discontinued
and, if the patient remains symptom-free, myocardial per-
fusion imaging with exercise or vasodilator stress, using either
sestamibi or dobutamine stress echocardiography, is under-
taken to delineate objective evidence of inducible ischemia. In
this strategy, persistence or recurrence of ischemic symptoms,
development of heart failure or hemodynamic instability, or a
positive stress test leads to prompt cardiac catheterization and
a more “selective” approach to intervention.
The central hallmark of both approaches is risk stratifi-
cation: the delineation of patients into subsets of high,
intermediate, or low risk depending on whether this is an
“anatomy driven” (based on coronary angiographic findings)
or an “ischemia-driven” (based on clinical presentation,
electrocardiogram [ECG] findings, serum inflammatory
and biomarkers, and the results of functional, non-invasive
testing) process. The relative merits of these approaches
have been tested in four large randomized trials: Throm-
bolysis in Myocardial Infarction (TIMI) IIIB, Veterans
Affairs Non–Q-Wave Infarction Strategies in-Hospital
(VANQWISH), Fragmin and Fast Revascularization dur-
ing Instability in Coronary artery disease (FRISC-II), and
the Treat Angina with Aggrastat and Determine Cost of
Therapy with an Invasive or Conservative Strategy
(TACTICS)-TIMI 18 (2–7) (Table 1).
Given the heterogeneous nature of patients who present
with NSTE ACS, the American College of Cardiology and
the American Heart Association promulgated joint guide-
lines in 2000 for the diagnosis, risk stratification, and manage-
ment of patients with NSTE ACS and endorsed both ap-
proaches (8). These guidelines provide a range of options that
are amenable to individual physician interpretation and hospi-
tal resource availability. However, in light of more recent
studies, including newer reports and analyses from the
FRISC-II and TACTICS-TIMI 18 trials, among others,
there is an intensifying movement to recommend a “routine
early invasive strategy” for all patients with NSTE ACS
regardless of their initial risk stratum. Based on the results of
these studies, is this an appropriate and rational approach?
In the FRISC-II trial, which was published originally in
the Lancet, 2,457 patients with unstable coronary disease
were randomized after 48 h to an invasive or noninvasive
approach (5). The invasive approach included catheteriza-
tion followed by revascularization within seven days, and the
noninvasive group had angiography followed by revascular-
ization for a markedly positive exercise test, refractory or
severe angina, or MI. All patients were treated with aspirin,
intravenous nitroglycerin, beta-blockers, and low-
molecular-weight heparin (dalteparin) for four to six days
until revascularization was performed in the invasive group
(78% of patients underwent PCI or bypass surgery) or for a
similar duration in the noninvasive group, 38% of whom
crossed over to revascularization during follow-up. At six
months, the rate of death or MI was significantly lower in
the invasive group (9.4%) compared with the noninvasive
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group (12.1%); the difference was primarily due to a lower
rate of MI (7.8% vs. 10.1%), while the difference in
mortality was not significant. Of note, the greatest benefit
was observed in high-risk patients who had signs of necrosis
or ischemia (only patients who had initial ST-segment
depression [45%] or biochemical markers of myocardial
damage [45%] benefited significantly from the invasive
strategy). There was a 50% reduction in angina and the need
for subsequent readmission with the invasive approach.
Importantly, these beneficial results were maintained at
one year of follow-up (6). Compared with the non-invasive
strategy, the invasive group had significantly lower rates of
mortality (2.2% vs. 3.9%), MI (8.6% vs. 11.6%), readmission
(37% vs. 57%), and need for revascularization after the
initial admission (7.5% vs. 31%).
In this current issue of the Journal, Lagerqvist et al. (9)
report on the important 24-month follow-up of the FRISC
II cohort, which showed a consistent reduction and contin-
ued separation of the event-curves between the two strate-
gies at two years. The predominant benefit between the two
groups, however, was still most apparent within the first 6 to
12 months. For example, during the first 12 months, 27
deaths occurred in the invasive arm compared with 48 in the
non-invasive arm, whereas between one and two years there
were 18 and 19 deaths, respectively. For each six-month
analysis interval beyond the first year (e.g., 13th to 18th
month, 19th to 24th month), there were strong trends for
reductions in the endpoint of MI and death or MI for the
invasive strategy, but the 95% confidence intervals sur-
rounding these individual risk ratios crossed the unity
boundary and were not, hence, statistically significant. For
the separate two-year end points of need for myocardial
revascularization and readmissions, the invasive strategy was
superior to the non-invasive strategy, indicating an impor-
tant salutary effect in reducing cardiac morbidity.
These findings mirrored the results of the TACTICS-
TIMI 18 trial, which randomly assigned 2,220 patients with
ACS or NSTEMI to an invasive strategy (catheterization
within 4 to 48 h and revascularization with PCI/stenting or
bypass surgery, if feasible) or a conservative strategy; all
patients received aspirin, beta-blockers, heparin, and tirofi-
ban for 48 to 108 h (7). At six months, the primary endpoint
(death, MI, rehospitalization for an ACS) was significantly
lower with the invasive strategy (15.9%) compared with the
conservative strategy (19.4%); the rate of death or nonfatal
MI was also reduced (7.3% vs. 9.5%). As in FRISC-II, the
majority of benefit for the invasive strategy was observed in
patients with NSTE ACS who initially displayed ST-
segment depression on the entry ECG (37% of patients)
and those who were biomarker-positive (54% of patients);
the clinical outcomes of patients who did not have ST-
segment depression or abnormal troponin on admission did
not differ between the invasive or conservative strategies.
Obviously, differences in clinical outcomes among these
four randomized studies can be explained by the fact
that the TIMI IIIB and VANQWISH trials were con-
ducted in the pre–glycoprotein (GP) IIb/IIIa inhibitor
therapy era and before the advent and widespread use of
stents (Table 2), whereas newer adjunctive pharmaco-
therapies were employed in FRISC-II (dalteparin) and
TACTICS (tirofiban), as well as stent usage (65% in
FRISC-II and 84% in TACTICS-TIMI 18). Moreover,
TIMI-IIIB, VANQWISH, and FRISC-II all showed an
increased hazard associated with the “routine early invasive
strategy”; namely, there was an approximately 60% excess
MI rate within the first two weeks with this approach in
Table 1. Conservative Versus Invasive Strategies in ACS—Four Randomized Clinical Trials
TIMI IIB VANQWISH FRISC-II TACTICS
Years 1989–1992 1993–1995 1996–1998 1998–2000
Countries U.S./Canada U.S. Sweden/Denmark/Norway 83% U.S.
Hospitals Varied VA Varied Varied
Sites 25 15 58 169
Patients 1,493 920 2,457 2,220
UA/NSTEMI 68%/32% 0%/100% 41%/59% 62%/38%
ACS  acute coronary syndrome; FRISC-II  Fragmin and Fast Revascularization during Instability in Coronary artery disease; NSTEMI  Non–ST-segment Elevation
Myocardial Infarction; TACTICS  Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy; TIMI  Thrombolysis in
Myocardial Infarction; UA  unstable angina; VA  Veterans Affairs; VANQWISH  Veterans Affairs Non–Q-Wave Infarction Strategies in-Hospital.
Table 2. Conservative Versus Invasive Strategies in ACS—Four Randomized Clinical Trials
TIMI IIB VANQWISH FRISC-II TACTICS
Background medications ASA, UFH ASA, UFH ASA, dalteparin ASA, UFH, tirofiban
Invasive arm—time to
cath
1.5 days 2 days 4 days 1 day
Stents 0% 0% 65% 84%
GP IIb/IIIa 0% 0% 10% 100%
CONS arm—threshold
to cath
Rec sx,  ST Holter
or ETT/TL201
Rec sx, ETT/TL201 Rec refr sx, ETT
(3 mm ST2)
Rec refr sx, ETT/tc 99
mibi or stress
echocardiography
  positive;   markedly positive; ASA  acetylsalicylic acid; Cath  coronary angiography; CONS  conservative; ETT  exercise stress test; GP  glycoprotein;
mibi  sestamibi; Rec  recurrence; refr  refractory; sx  symptoms; UFH  unfractionated heparin. Other abbreviations as in Table 1.
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patients with NSTE ACS, whereas in TACTICS this early
hazard was not observed, suggesting that tirofiban admin-
istration mitigated the adverse consequences of distal mi-
croembolization and incomplete platelet inhibition associ-
ated with early intervention.
Where does all of this leave the clinician in 2002–2003?
It now seems abundantly clear that high-risk (and probably
intermediate-risk) patients with NSTE ACS benefit from
an early invasive strategy and, as the current study suggests,
this beneficial effect is maintained during long-term follow-
up, although most of the benefit appears to be “front-
loaded” within the first year. This is, perhaps, not surprising
because one would presume that the major adverse effects of
reinfarction and post-infarction angina after an ACS would
be more likely to occur in the same vascular bed (either
restenosis or progression of native coronary disease) within
this time frame rather than a new event in a different
vascular bed. Development of new ACS late (1 to 2 years or
longer) after an initial intervention would be as—or more—
likely attributable to disease progression in a different
vascular bed and, hence, would not likely represent “cardio-
protection” from catheter-based or surgical intervention of
the original culprit stenosis.
Yet, it is also true that risk stratification remains an
important part of optimal clinical decision making today
because NSTE ACS is heterogeneous, representing a spec-
trum of risk ranging from low to high. A routine invasive
approach with acute revascularization for all patients is not
supported by even contemporary randomized trials (5–7)
and may not be cost-effective (10) (FRISC-II and
TACTICS did not demonstrate clear superiority for pa-
tients who were biomarker-negative and those without
ST-segment depression (5,7); FRISC-II also did not dem-
onstrate clear benefit for the routine invasive strategy in
women patients with unstable coronary disease—a sizeable
and growing segment of the population (11). Thus, 45%
to 50% of all NSTE ACS patients may fall into a category
where either a “routine invasive” or an “ischemia-guided”
(or “selective invasive”) approach may be appropriate.
Most important of all, aggressive pharmacologic
intervention is indicated in all patients with ACS regardless of
one’s approach to the role of mechanical intervention
or revascularization. Based on the results of multiple random-
ized trials, all patients, unless there is a contraindication, should
receive aspirin, clopidogrel, unfractionated heparin, or low-
molecular-weight heparin (two trials have shown the
superiority of enoxaparin compared with unfractionated hep-
arin in these patients (12,13), intravenous nitroglycerin (if
hemodynamically stable), a GP IIb/IIIa agent (in
intermediate- and high-risk patients, based on several studies
utilizing abciximab as part of an early PCI triage strategy
(14–17) or tirofiban/eptifibatide as “upstream therapy” in ACS
patients triaged to an initial non-invasive approach (18–24), a
beta-blocker and a statin (based on the results of two recent
studies (25,26)—all of which should be used in combination to
reduce clinical events. In particular, the results of the recent
Clopidogrel in Unstable angina to prevent Recurrent Events
(CURE) trial (27) demonstrate that all subsets of patients with
NSTE ACS benefited from clopidogrel regardless of age,
gender, presence or absence of ECG ST-segment depression
or biomarker positivity, or whether patients were managed
with an invasive or non-invasive approach.
Finally, it is important to emphasize that the long-term
benefits attributed to the “routine early invasive strategy” or
to myocardial revascularization alone, as Lagerqvist’s cur-
rent study suggests, as well as the TACTICS TIMI-18 trial
results, might actually be due, in part, to the aggressive
“polypharmacy” of antiplatelet, antithrombin, and anti-
ischemic therapy that was used in both trials as a prelude to
mechanical intervention or myocardial revascularization. The
concept of so-called “plaque passivation” has been advanced as
a potential explanation for the improved clinical outcomes that
may occur as a consequence of various pharmacologic “inter-
ventions” that could reduce oxidative stress, improve endothe-
lial function and vascular homeostasis, and reduce both inflam-
mation and microembolization (28–31).
Neither FRISC-II nor TACTICS evaluated the role of
very early mechanical intervention within hours of ACS
symptom onset. As noted earlier, all patients received aspirin,
heparin, or dalteparin (FRISC-II), tirofiban (TACTICS),
and anti-ischemic therapy (intravenous nitroglycerin fol-
lowed by beta-blockers) for at least 48 h after symptom
onset (TACTICS) or during the four to six days (FRISC-
II) that preceded revascularization in all subjects. Moreover,
one could hardly classify such a four- to six-day pretreat-
ment interval as being “Fast” Revascularization by North
American standards, as the “F” in FRISC-II connotes!
Thus, one might argue logically that “pharmacologic inter-
vention” as a prelude to “mechanical intervention” or revas-
cularization might be as—if not more—important to facil-
itating cardioprotection and reducing clinical events in
patients with ACS.
Perhaps it is time that we abandon attempts to categorize
or label cardiologists as “invasive” versus “non-invasive” or
“aggressive” versus “conservative,” because these dichoto-
mous classifications woefully oversimplify clinical decision
making and patient management. In reality, perhaps we are
all “interventional” cardiologists—some of us perform much
needed and highly effective mechanical interventions, while
many more of us engage in aggressive pharmacologic
intervention with or without mechanical intervention. It is
becoming increasingly clear that, if our therapeutic goals of
reducing death, recurrent MI, or ischemia and preserving or
enhancing quality of life in patients with ACS are to be
optimized, the best clinical outcomes can be achieved by
coupling mechanical intervention and revascularization with
intensive, multifaceted pharmacologic intervention as part
of an integrated, two-pronged approach that embodies
treatment of coronary culprit stenoses together with sys-
temic multidimensional medical therapy.
In summary, the treatment of patients with ACS remains
a difficult moving target for the clinician. Incorporating the
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latest advances in pharmacotherapy and catheter-based
revascularization into clinical practice, and perhaps more
importantly, using a combination of pharmacologic and
mechanical interventions in ACS patients at risk for con-
tinued morbidity and mortality is of paramount importance
to achieving true cardioprotection and prolonging both
short- and long-term event-free survival.
Addendum
Since the time this Editorial went to press, the RITA-3 Trial has
been published (Lancet 2002;360:743–51) and has shown that an
interventional strategy is preferable to a conservative strategy in
1,810 patients with NSTE ACS. The difference was mainly due to
a reduction of refractory angina in the interventional group, but
there was an increased incidence of early procedural events (MI)
and worse outcomes in women patients assigned to the interven-
tional strategy.
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